Novel drug delivery systems in pain therapy

Minerva Anestesiologica

Volumn 73, Issue 3, 2007, Pages 173-179

  Al Malyan, M ^a   Becchi, C ^a   Boncinelli, S ^a   Ashammakhi, N ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Biodegradable materials; Controlled drug delivery systems; Pain; Polymers

Indexed keywords

BUPIVACAINE; CHITOSAN; COLLAGEN; DENDRIMER; DEXAMETHASONE; DEXTRAN; GELATIN; HYALURONIC ACID; LECTIN; LOCAL ANESTHETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; POLY(ORTHO ESTER); POLYAMINOACID; POLYESTER; POLYETHYLENE; POLYETHYLENE TEREPHTHALATE; POLYGLACTIN; POLYHYDROXYALKANOIC ACID; POLYLACTIC ACID; POLYMER; POLYPROPYLENE; POLYSILOXANE; POLYVINYLCHLORIDE; RUBBER; SILICONE; STEROID;

ANALGESIA; BIODEGRADABLE IMPLANT; CHRONIC PAIN; DRUG DELIVERY SYSTEM; HUMAN; INFUSION PUMP; INTERCOSTAL NERVE BLOCK; MICROCAPSULE; PAIN THRESHOLD; POSTOPERATIVE PAIN; RESERVOIR; REVIEW;

ANALGESICS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS; PAIN;

EID: 34249092645     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. IASP International Association for the Study of Pain. IASP Pain Terminology [IASP web site]. November 9, 2004. http://www.iasp-pain.org/ terms-p.html
2. Smith BH, Elliott AM, Chambers WA, Cairns Smith W, Hannaford PC, Penny K. The impact of chronic pain in the community. Fam Pract 2001;18:292-9.
3. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA 1998;280:147-51.
4. Bowsher D, Rigges M, Sopp L. Prevalence of chronic pain in the British population: a telephone survey of 1037 households. Pain Clin 1991;4:223-30.
5. Andersson HI, Ejlertsson G, Leden I, Rosenberg C. Chronic pain in a geographically defined population: studies of differences in age, gender, social class, and pain localization. Clin J Pain 1993;9:174-82.
6. World Health Organization. WHO Guidelines: Cancer Pain Relief (2nd). Geneve, Switzerland: World Health Organization; 1996.
7. Breaking pain barriers. The white paper on opiods and pain: A pan-european challenge. A Report compiled by OPEN Minds (Opioids and Pain European Network of Minds) June 2005. www.eurpeanpainnetwork.com/ files/White_Paper.pdf.
8. Andersen S, Worm-Pedersen J. The prevalence of persistent pain in a Danish population. Pain 1987;S4:S332.
9. Von Korff M, Dworkin SF, LeResche L, Kruger A. An epidemiologic comparison of pain complaints. Pain 1988;32: 173-83.
10. Higginson IJ. Innovations in assessment: epidemiology and assessment of pain in advanced cancer. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z editors. Proceedings of the 8th World Congress on pain, Progress in Pain Research and Management. Seattle: IASP Press; 1997;8:707-11.
11. Zimmermann M. Chronic pain. Epidemiology and management in Germany. Orthopade 2004;33:508-14.
12. Parrott T. Pain management in primary-care medical practice. In: Tollison CD, Satterthwaithe JR, Tollison JW, editors. Practical Pain Management. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2002.p.729-59.
13. Loeser JD, Butler SH, Chapman CR, Turk KC. Bonica's Management of pain. 3rd ed. Philadelphia, PA: Lippincott Williams & Willkins; 2001.
14. Stucky CL, Michael S. Gold, Xu Z. Mechanisms of pain 2000. Proc Natl Acad Sci U S A 2001;98:11845-6.
15. Langer R. Implantable controlled release systems. Pharmacol Ther 1983;21:35-51.
16. Danckwerts M, Fassihi A. Implantable controlled release drug delivery systems: a review. Drug Dev Ind Pharm 1991;17:1465-502.
17. Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998;40:1-12.
18. Ranade V. Drug delivery systems. 4. Implants in drug delivery. J Clin Pharmacol 1990;30:871-89.
19. Baker R. Controlled release of biologically active agents. New York: John Wiley and Sons; 1987.
20. Pillai O, Panchangnula R. Polymers in drug delivery. Curr Opin Chem Biol 2001;5:447-51.
21. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003;24:3311-31.
22. Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater 2003;5:1-16.
23. Gopferich A, Tessmar J. Polyanhydride degradation and erosion. Adv Drug Deliv Rev 2002;54:911-31.
24. Winzenburg G, Schmidt C, Fuchs S, Kissel T. Biodegradable polymers and their potential use in parenteral veterinary drug delivery systems. Adv Drug Deliv Rev 2004;56:1453-66.
25. Vert M. Aliphatic polyesters: great degradable polymers that cannot do everything. Biomacromolecules 2005;6:538-46.
26. Heller J, Barr J. Poly(ortho esters) - from concept to reality. Biomacromolecules 2004;5:1625-32.
27. Wakiyama N, Juni K, Nakano M. Preparation and evaluation in vitro of polylactic acid microspheres containing local anesthetics. Chem Pharm Bull (Tokyo) 1981;29:3363-8.
28. Estebe JP, Le Corre P, Malledant Y, Chevanne F, Leverge R. Prolongation of spinal anesthesia with bupivacaine-loaded (DL-lactide) microspheres. Anesth Analg 1995;81:99-103.
29. Estebe JP, Le Corre P, Clement R, Du Plessis L, Chevanne F, Le Verge R et al. Effect of dexamethasone on motor brachial plexus block with bupivacaine and with bupivacaine-loaded microspheres in a sheep model. Eur J Anaesthesiol 2003;20:305-10.
30. Curley J, Castillo J, Hotz J, Uezono M, Hernandez S, Lim JO et al. Prolonged regional nerve blockade. Injectable biodegradable bupivacaine/ polyester microspheres. Anesthesiology 996;84:1401-10.
31. Tunçay M, Calis S, Kas HS. Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation. Int J Pharm 2000;195:179-88.
32. Suter MR, Papaloizos M, Berde CB. Development of neuropathic pain in the rat spared nerve injury model is not prevented by a peripheral nerve block. Anesthesiology 2003;99:1402-8.
33. Salman MA, Sahin A, Onur MA. Tramadol encapsulated into polyhydroxybutyrate microspheres: in vitro release and epidural analgesic effect in rats. Acta Anaesthesiol Scand 2003;47:1006-12.
34. Doherty MM, Hughes PJ, Korszniak NV. Prolongation of lidocaine-induced epidural anesthesia by medium molecular weight hyaluronic acid formulations: pharmacodynamic and pharmacokinetic studies in the rabbit. Anesth Analg 1995;80:740-6.
35. Paavola A, Yliruusi J, Kajimoto Y. Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block. Pharm Res 1995;12:1997-2002.
36. Mahkam M, Allahverdipoor M. Controlled release of biomolecules from pH-sensitive network polymers prepared by radiation polymerization. J Drug Target 2004;12:151-6.
37. Sendil-Keskin D, Altunay H, Wise DL. In vivo pain relief effectiveness of an analgesic-anesthetic carrying biodegradable controlled release rod systems. J Biomater Sci Polym Ed 2003;14:497-514.
38. Hasirci V, Bonney I, Goudas LC. Antihyperalgesic effect of simultaneously released hydromorphone and bupivacaine from polymer fibers in the rat chronic constriction injury model. Life Sci 2003;73:3323-37.
39. Masters DB1, Berde CB, Ward JM. Biochemical and histologic effects of prolonged sciatic nerve blockade with bupivacaine using a biodegradable polymer matrix. Anesthesiology 1991;75(3A):A680.
40. Garry MG, Jackson DL, Geier HE. Evaluation of the efficacy of a bioerodible bupivacaine polymer system on antinociception and inflammatory mediator release. Pain 1999;82: 49-55.
41. Chandrashekar G, Udupa N. Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers. J Pharm Pharmacol 1996;48: 669-74.
42. Sato S, Baba Y, Tajima K. Prolongation of epidural anesthesia in the rabbit with the use of a biodegradable copolymer paste containing lidocaine. Anesth Analg 1995;80:97-101.
43. Sahota TS, Latham RJ, Linford RG. In vitro iontophoretic release of lithium chloride and lidocaine hydrochloride from polymer electrolytes. Drug Dev Ind Pharm 2000;26:1039-44.
44. Conforti A, Bertani S, Lussignoli S. Anti-inflammatory activity of polyphosphazene-based naproxen slow-release systems. J Pharm Pharmacol 1996;48:468-73.
45. Seo SA, Choi HS, Khang G. A local delivery system for fentanyl based on biodegradable poly(L-lactide-co-glycolide) oligomer. Int J Pharm 2002;239:93-101.
46. Lubach JW, Padden BE, Winslow SL. Solid-state NMR studies of pharmaceutical solids in polymer matrices. Anal Bioanal Chem 2004;378:1504-10.
47. Sendil KD, Wise DL, Hasirci V. Pain control via opioid analgesic - local anesthetic loaded IPNs. Curr Drug Delivery 2004;1:57-64.
48. Choi HS, Seo SA, Khang G. Preparation and characterization of fentanyl-loaded PLGA microspheres: in vitro release profiles. Int J Pharm 2002;234:195-203.
49. Estebe JP, Ecoffey C, Dollo G. Bupivacaine pharmacokinetics and motor blockade following epidural administration of the bupivacaine-sulphobutylether 7-beta-cyclodextrin complex in sheep. Eur J Anaesthesiol 2002;19:308-10.
50. Drager C, Benziger D, Gao F. Prolonged intercostal nerve blockade in sheep using controlled-release of bupivacaine and dexamethasone from polymer microspheres. Anesthesiology 1998;89:969-79.
51. Wakiyama N, Juni K, Nakano M. Duration of the local anesthetic effect of tetracaine hydrochloride solutions and tetracaine in microspheres. J Pharmacobiodyn 1982;5:13-7.
52. Le Corre P, Estebe JP, Chevanne F. Spinal controlled delivery of bupivacaine from DL-lactic acid oligomer microspheres. J Pharm Sci 1995;84:75-8.
53. Maszczynska Bonney I, Sendil Keskin D, Lipkowski AW, Hasirci V, Carr DB. Advances in analgesic drug design and delivery: a current survey. Adv Exp Med Biol 2004;553: 209-19.
54. Kopacz DJ, Allen HW, Hopt K. Extended local anesthesia of bupivacaine-loaded microspheres-role of dexamethasone. Anesth Analg 2001;92:S260.
55. Holte K, Werner MU, Lacouture PG, Kehlet H. Dexamethasone prolongs local anesthesia after subcutaneous infiltration of bupivacaine microcapsu- les in human volunteers. Anesthesiology 2002;96:1331-5.
56. Kopacz DJ, Bernards CM, Allen HW, Landau C, Nandy P, Wu D et al. A model to evaluate the pharmacokinetic and pharmacodynamic variables of extended- release products using in vivo tissue microdialysis in humans: bupivacaine-loaded microcapsules. Anesth Analg 2003;97:124-31.
57. Kopacz DJ, Lacouture PG, Wu D, Nandy P, Swanton R, Landau C. The dose response and effects of dexamethasone on bupivacaine microcapsules foe intercostal blockade (T9 to T11) in healthy volunteers. Anesth Analg 2003;96:576-82.
58. Pedersen JL, Lillesø J, Hammer NA, Werner MU, Holte K, Lacouture PG et al. Bupivacaine in microcapsules prolong analgesia after subcutaneous infiltration in humans: a dosefinding study. Anesth Analg 2004;99:912-8.